News

Sun Pharma shares jump 9% after drugmaker announces Organon deal at $11.75 billion Enterprise ValueSun Pharma also said that the proposed acquisition aligns with the company's strategy of growing its innovative medicines business and that it enables the company's entry into Biosimilars as a top-10 global player.By Ekta Batra   |  Vivek Iyer   |  Hormaz Fatakia   April 27, 2026, 11:35:57 AM IST (Updated)2 Min ReadIndia's largest drugmaker, Sun Pharmaceuticals Ltd., has announced on Monday, April 27, that it has signed a definitive agreement to acquire US-listed Organon for sustained, long-term value creation and complementary portfolios that will enhance its business leverage. The stock has jumped 9% in response to the transaction and is among the top Nifty gainer.

Sun Pharma will acquire 100% of Organon's outstanding equity at an enterprise value of $11.75 billion, it said in an exchange filing.

Shareholders of Organon will be liable to receive $14 per share in cash, which is a 24% premium to the stock's closing price on Friday. Shares of Organon have already doubled in value since April 8 this year, when reports of this transaction first began to surface. This includes a 30% jump in the stock last Friday itself.

CNBC-TV18 had reported on Saturday, April 25, that the deal is one-step closer and that it will be announced soon.

Sun Pharma also said that the proposed acquisition aligns with the company's strategy of growing its innovative medicines business and that it enables the company's entry into Biosimilars as a top-10 global player.

Sun Pharma plans on funding the deal through a combination of available cash resources and committed financing from banks. This transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma and is likely to close in early 2027, subject to customary conditions including approval from Organon's existing shareholders and other regulatory approvals.

Here's how the transaction benefits Sun Pharma:

Among top 25 global pharmaceutical companies with a combined revenue of $12.4 billion

A leading player in established branded generics

A more innovative medicines-focused company with 27% revenue share

A top 3 company in global women's health, creating a commercial platform for future growth

Seventh largest biosimilar playerOrganon was created through a spin-off from Merck & Co. in 2025. For financial year 2025, the company reported revenue of $6.2 billion along with an adjusted Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) figure of $1.9 billion.The company currently has $574 million in cash on the books and debt worth $8.6 billion. It will also receive $440 million from a recent divestment.

Shares of Sun Pharma are trading 4.8% higher on Monday at ₹1,698.6. The stock had ended at the day's low last Friday.

Also Read: Sun Pharma-Organon Deal: Analysts advice what to do with the stock after the newsContinue ReadingFirst Published: Apr 27, 2026 5:52 AM ISTTagsM&Ashare market todaySun PharmaSun Pharma Share PriceSun pharma shares